The Rise of Dilip Shanghvi's Global Pharmaceutical Empire: Unpacking the Architectural Underpinnings

Sun Pharmaceutical Seals $11.75 Billion Deal to Acquire Organon & Co.

Mumbai: In a significant move, Dilip Shanghvi, the chairman of Sun Pharmaceutical, recently walked into a press conference to announce the company's acquisition of Organon & Co. in a deal worth $11.75 billion. This acquisition is expected to effectively double Sun Pharmaceutical's revenue to $12.4 billion.

The acquisition marks a major milestone for Sun Pharmaceutical, a leading Indian pharmaceutical company, as it expands its global footprint. The deal is expected to significantly enhance Sun Pharmaceutical's presence in the US market, where Organon & Co. has a strong presence. Organon & Co.'s portfolio of established brands and products will complement Sun Pharmaceutical's existing portfolio, enabling the company to tap into new markets and increase its revenue streams.

Sun Pharmaceutical will acquire Organon & Co. in an all-cash deal, with the acquisition expected to be completed in the third quarter of 2023. The acquisition is subject to regulatory approvals and other customary closing conditions. Sun Pharmaceutical has been on an acquisition spree in recent years, and this deal is part of the company's strategy to expand its global presence and increase its revenue.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data